Cargando…
S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428338/ http://dx.doi.org/10.1097/01.HS9.0000967980.32472.94 |
| _version_ | 1785090444696223744 |
|---|---|
| author | Heeney1, Matthew Rees, David de Montalembert, Mariane Odame, Isaac Wali, Yasser Sayyed, Sarfaraz Shanmuganathan Muthusamy, Velusamy Mendonza, Anisha E. Nassin, Michele Keefe, Deborah Kanter, Julie |
| author_facet | Heeney1, Matthew Rees, David de Montalembert, Mariane Odame, Isaac Wali, Yasser Sayyed, Sarfaraz Shanmuganathan Muthusamy, Velusamy Mendonza, Anisha E. Nassin, Michele Keefe, Deborah Kanter, Julie |
| author_sort | Heeney1, Matthew |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428338 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104283382023-08-17 S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY Heeney1, Matthew Rees, David de Montalembert, Mariane Odame, Isaac Wali, Yasser Sayyed, Sarfaraz Shanmuganathan Muthusamy, Velusamy Mendonza, Anisha E. Nassin, Michele Keefe, Deborah Kanter, Julie Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428338/ http://dx.doi.org/10.1097/01.HS9.0000967980.32472.94 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Heeney1, Matthew Rees, David de Montalembert, Mariane Odame, Isaac Wali, Yasser Sayyed, Sarfaraz Shanmuganathan Muthusamy, Velusamy Mendonza, Anisha E. Nassin, Michele Keefe, Deborah Kanter, Julie S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY |
| title | S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY |
| title_full | S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY |
| title_fullStr | S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY |
| title_full_unstemmed | S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY |
| title_short | S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY |
| title_sort | s267: pharmacokinetics/pharmacodynamics, safety and efficacy of crizanlizumab in patients with sickle cell disease aged 12 to <18 years: 2-year data from the phase 2 solace-kids study |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428338/ http://dx.doi.org/10.1097/01.HS9.0000967980.32472.94 |
| work_keys_str_mv | AT heeney1matthew s267pharmacokineticspharmacodynamicssafetyandefficacyofcrizanlizumabinpatientswithsicklecelldiseaseaged12to18years2yeardatafromthephase2solacekidsstudy AT reesdavid s267pharmacokineticspharmacodynamicssafetyandefficacyofcrizanlizumabinpatientswithsicklecelldiseaseaged12to18years2yeardatafromthephase2solacekidsstudy AT demontalembertmariane s267pharmacokineticspharmacodynamicssafetyandefficacyofcrizanlizumabinpatientswithsicklecelldiseaseaged12to18years2yeardatafromthephase2solacekidsstudy AT odameisaac s267pharmacokineticspharmacodynamicssafetyandefficacyofcrizanlizumabinpatientswithsicklecelldiseaseaged12to18years2yeardatafromthephase2solacekidsstudy AT waliyasser s267pharmacokineticspharmacodynamicssafetyandefficacyofcrizanlizumabinpatientswithsicklecelldiseaseaged12to18years2yeardatafromthephase2solacekidsstudy AT sayyedsarfaraz s267pharmacokineticspharmacodynamicssafetyandefficacyofcrizanlizumabinpatientswithsicklecelldiseaseaged12to18years2yeardatafromthephase2solacekidsstudy AT shanmuganathanmuthusamyvelusamy s267pharmacokineticspharmacodynamicssafetyandefficacyofcrizanlizumabinpatientswithsicklecelldiseaseaged12to18years2yeardatafromthephase2solacekidsstudy AT mendonzaanishae s267pharmacokineticspharmacodynamicssafetyandefficacyofcrizanlizumabinpatientswithsicklecelldiseaseaged12to18years2yeardatafromthephase2solacekidsstudy AT nassinmichele s267pharmacokineticspharmacodynamicssafetyandefficacyofcrizanlizumabinpatientswithsicklecelldiseaseaged12to18years2yeardatafromthephase2solacekidsstudy AT keefedeborah s267pharmacokineticspharmacodynamicssafetyandefficacyofcrizanlizumabinpatientswithsicklecelldiseaseaged12to18years2yeardatafromthephase2solacekidsstudy AT kanterjulie s267pharmacokineticspharmacodynamicssafetyandefficacyofcrizanlizumabinpatientswithsicklecelldiseaseaged12to18years2yeardatafromthephase2solacekidsstudy |